Abstract
Drug development for neuroscience or targeting the brain is challenging and considered a complex research area in pharmaceutical sciences. To act upon these drugs should be able to reach their site of action. However, these sites are protected from all external entities by several barriers. The blood–brain barrier (BBB) prevents the entry of many drugs, including antibiotics, neuropeptides Etc. The complexity of brain disorders and the presence of BBB prevents the development of drugs. The past decade has seen a boom in the drug delivery methods for treatment in neuroscience. One reason for this is the alarming increase in the neurological diseases observed. The other reason is that a lot of information is now available about the CNS and a better understanding of the methods and the drug interaction through which efficient drug delivery can occur. Many strategies like colloidal drug carriers, cell-penetrating peptides, receptor and carrier-mediated transport need further research.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- BBB:
-
Blood Brain Barrier
- CNS:
-
Central Nervous System
- DALY:
-
Years of Life Lost (YLL)
- YLD:
-
Years Lived with Disability
- CMT:
-
Carrier Mediated Transport
- RMT:
-
Receptor Mediated Transport
- CDDS:
-
Chemical Drug Delivery System
- CSF:
-
Cerebrospinal Fluid
- CPP:
-
Cell Penetrating Peptides
- FUS:
-
focused ultrasound
- Tf:
-
iron binding protein transferrin
- TfR:
-
Tf receptor
- PEG-PLA:
-
Poly ethylene glycol-poly lactic acid
References
Banks WA (2016) From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov 15:275–292
Goyal D, Shuaib S, Mann S, Goyal B (2017) Rationally Designed Peptides and peptidomimetics as inhibitors of amyloid-β (Aβ) aggregation: potential therapeutics of Alzheimer’s disease. ACS Comb Sci 19:55–80
Reese TS, Karnovsky MJ (1967) Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34:207–217
Brightman MW, Reese TS (1969) Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 40:648–677
Engelhardt B, Sorokin L (2009) The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 31:497–511
Lund-Andersen H (1979) Transport of glucose from blood to brain. Physiol Rev 59:305–352
Saunders NR et al (2014) The rights and wrongs of blood-brain barrier permeability studies: a walk through 100 years of history. Front Neurosci 8
Stewart PA, Tuor UI (1994) Blood-eye barriers in the rat: Correlation of ultrastructure with function. J Comp Neurol 340:566–576
Feigin VL et al (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:459–480
Rodriguez A, Tatter S, Debinski W (2015) Neurosurgical techniques for disruption of the blood-brain barrier for glioblastoma treatment. Pharmaceutics 7:175–187
Gumerlock M, Belshe B, Madsen R, Watts C (1992) Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review. J Neurooncol 12
Mukhopadhyay A, Mukhopadhyay B, Basu SK (1995) Circumvention of multidrug resistance in neoplastic cells through scavenger receptor mediated drug delivery. FEBS Lett 376:95–98
Misra A, Ganesh S, Shahiwala A, Shah SP (2003) Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 6:252–273
Taylor EM (2002) The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 41:81–92
Craparo EF, Bondì ML, Pitarresi G, Cavallaro G (2011) Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neurosci Ther 17:670–677
Duskey JT et al (2017) Current strategies for the delivery of therapeutic proteins and enzymes to treat brain disorders, Int Rev Neuroboiol 137:1–28
Buchwald P, Bodor N (2001) A simple, predictive, structure-based skin permeability model. J Pharm Pharmacol 53:1087–1098
Alessandrini A, Namura S, Moskowitz MA, Bonventre JV (1999) MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc Natl Acad Sci 96:12866–12869
Deol P, Khuller G (1997) Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta Gen Subj 1334:161–172
Kshirsagar NA, Pandya SK, Kirodian GB, Sanath S (2005) Liposomal drug delivery system from laboratory to clinic. J Postgrad Med 51(Suppl 1):S5-15
Shapira I, Budman DR, Bradley T, Gralla R (2009) Evolving lipid-based delivery systems in the management of neoplastic disease. Oncol Rev 3:113–124
Uppadhyay AK, Dixit VK (1998) Bioadhesive liposomes bearing levonorgestrel as controlled drug delivery system. Pharmazie 53:421–422
Karande SC et al (1995) Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B (L-AmpB-LRC) in a child. Trop Doct 25:80–81
Pardridge WM (2007) shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev 59:141–152
Jain NK, Rana AC, Jain SK (1998) Brain drug delivery system bearing dopamine hydrochloride for effective management of parkinsonism. Drug Dev Ind Pharm 24:671–675
Yang S, Zhu J, Lu Y, Liang B, Yang C (1999) Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 16:751–757
Saraiva C et al (2016) Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release 235:34–47
Huang L, Liu Y (2011) In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 13:507–530
Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA (2008) Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv 5:155–174
Lee J, Duan W, Mattson MP (2002) Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem 82:1367–1375
Wohlfart S, Gelperina S, Kreuter J (2012) Transport of drugs across the blood–brain barrier by nanoparticles. J Control Release 161:264–273
Deo MR, Sant VP, Parekh SR, Khopade AJ, Banakar UV (1997) Proliposome-based transdermal delivery of levonorgestrel. J Biomater Appl 12:77–88
Tiwari G et al (2012) Drug delivery systems: an updated review. Int J Pharm Investig 2:2
Juillerat-Jeanneret L (2008) The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 13:1099–1106
Pirollo KF et al (2016) Safety and efficacy in advanced solid tumors of a targeted nanocomplex carrying the p53 gene used in combination with docetaxel: a phase 1b study. Mol Ther 24:1697–1706
Bramini M et al (2014) Imaging approach to mechanistic study of nanoparticle interactions with the blood-brain barrier. ACS Nano 8:4304–4312
Rautio J, Laine K, Gynther M, Savolainen J (2008) Prodrug approaches for CNS delivery. AAPS J 10:92–102
Oldendorf WH, Hyman S, Braun L, Oldendorf SZ (1972) Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 80–178:984–986
Chen K-T, Wei K-C, Liu H-L (2019) Theranostic strategy of focused ultrasound induced blood-brain barrier opening for CNS disease treatment. Front Pharmacol 10
Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N (2005) Local and reversible blood–brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 24:12–20
McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS (2012) Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in Rhesus Macaques. Cancer Res 72:3652–3663
Vykhodtseva NI, Hynynen K, Damianou C (1995) Histologic effects of high intensity pulsed ultrasound exposure with subharmonic emission in rabbit brain in vivo. Ultrasound Med Biol 21:969–979
Vykhodtseva N, McDannold N, Hynynen K (2008) Progress and problems in the application of focused ultrasound for blood–brain barrier disruption. Ultrasonics 48:279–296
Burgess A, Hynynen K (2014) Drug delivery across the blood–brain barrier using focused ultrasound. Expert Opin Drug Deliv 11:711–721
Bodor N, Buchwald P (2010) Retrometabolism-based drug design and targeting. In: Burger’s medicinal chemistry and drug discovery. Wiley & Sons, Inc. Pharmazie 65(6):395–403
Alvarez-Erviti L et al (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29:341–345
Zhuang X et al (2011) Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther 19:1769–1779
Matsumoto J et al (2017) Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson’s disease? Acta Neuropathol Commun 5:71
Chen CC et al (2016) Elucidation of exosome migration across the blood-brain barrier model in vitro. Cell Mol Bioeng 9:509–529
Dutta D, Donaldson JG (2012) Search for inhibitors of endocytosis. Cell Logist 2:203–208
Haney MJ et al (2015) Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J Control Release 207:18–30
Liu Y et al (2015) Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse. Sci Rep 5:17543
Qin Y et al (2011) Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm 420:304–312
Wei X et al (2015) A D-Peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. Angew Chemie Int Ed. 54:3023–3027
DĂaz-Perlas C et al (2017) Phage display as a tool to discover blood-brain barrier (BBB)-shuttle peptides: panning against a human BBB cellular model. Biopolymers 108, e22928
Thom G et al (2018) Isolation of blood-brain barrier-crossing antibodies from a phage display library by competitive elution and their ability to penetrate the central nervous system. MAbs 10:304–314
Xiao G, Gan LS (2013) Receptor-mediated endocytosis and brain delivery of therapeutic biologics. Int J Cell Biol (2013)
Pulgar VM (2019) Transcytosis to cross the blood brain barrier, new advancements and challenges. Front Neurosci 13:1–9
Rodriguez-Boulan E, Kreitzer G, Müsch A (2005) Organization of vesicular trafficking in epithelia. Nat Rev Mol Cell Biol 6:233–247
Gregori M et al (2016) Novel antitransferrin receptor antibodies improve the blood-brain barrier crossing efficacy of immunoliposomes. J Pharm Sci 105:276–283
Boado RJ et al (2008) Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng 99:475–484
Pardridge WM, Boado RJ (2012) Reengineering biopharmaceuticals for targeted delivery across the blood–brain barrier, Methods Enzymol 503:269–292
Boado RJ, Hui EK-W, Lu JZ, Pardridge WM (2012) Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metab Dispos 40:2021–2025
Pardridge WM (2008) Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug Chem 19:1327–1338
Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA (2010) Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer’s amyloid β-peptide elimination from the brain. J Neurochem 115:1077–1089
Kanwar JR, Sriramoju B, Kanwar RK (2012) Neurological disorders and therapeutics targeted to surmount the blood-brain barrier. Int J Nanomedicine 7:3259–3278
Demeule M et al (2008) Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 324:1064–1072
van Rooy I et al (2010) Identification of peptide ligands for targeting to the blood-brain barrier. Pharm Res 27:673–682
Pardridge WM, Oldendorf WH (1975) Kinetics of blood-brain barrier transport of hexoses. Biochim Biophys Acta Biomembr 382:377–392
Valentinuzzi ME, Friedman LM, Furberg CD, DeMets DL (2004) Fundamentals of clinical trials, 3rd edn. Biomed Eng 3:43
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Jose, D.A., Krishnapriya, Baby Chakrapani, P.S. (2022). Containers Based Drug Delivery for Neuroscience. In: Parameswaranpillai, J., V. Salim, N., Pulikkalparambil, H., Mavinkere Rangappa, S., Suchart Siengchin, I.h. (eds) Micro- and Nano-containers for Smart Applications. Composites Science and Technology . Springer, Singapore. https://doi.org/10.1007/978-981-16-8146-2_14
Download citation
DOI: https://doi.org/10.1007/978-981-16-8146-2_14
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-8145-5
Online ISBN: 978-981-16-8146-2
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)